Table 4.

Adverse events at first follow-up divided by diagnosis and linaclotide dose

	72 µg	145 µg	290 µg
Functional constipation	N = 10	N = 50	N = 0
No adverse events, n (%)	4 (40)	36 (72)	n/a
Adverse events, n (%)	6 (60)	14 (28)	n/a
Diarrhea, n (%)	2 (20)	5 (10)
Abdominal pain, n (%)	1 (10)	6 (12)
Nausea, n (%)	1 (10)	3 (6.0)
Flatulence, n (%)	2 (20)	2 (4.0)
Fecal incontinence, n (%)	1 (10)	2 (4.0)
Bloating, n (%)	1 (10)	1 (2.0)
Irritable bowel syndrome with constipation	N = 4	N = 28	N = 1
No adverse events, n (%)	3 (75)	16 (57)	0 (0)
Adverse events, n (%)	1 (25)	12 (43)	1 (100)
Diarrhea, n (%)	0 (0)	10 (36)	0 (0)
Abdominal pain, n (%)	1 (25)	2 (7.1)	1 (100)
Nausea, n (%)	0 (0)	2 (7.1)	1 (100)
Flatulence, n (%)	0 (0)	0 (0)	0 (0)
Fecal incontinence, n (%)	0 (0)	1 (3.6)	0 (0)
Bloating, n (%)	0 (0)	0 (0)	1 (100)